当前位置: 首页 > 期刊 > 《中国民族民间医药杂志》 > 2009年第10期
编号:11780119
紫杉醇联合卡培他滨治疗进展期胃癌的临床观察
http://www.100md.com 2009年5月15日 《中国民族民间医药杂志》 2009年第10期
紫杉醇联合卡培他滨治疗进展期胃癌的临床观察

     【摘要】目的:观察紫杉醇联合卡培他滨(希罗达)作为二线方案治疗晚期胃癌的有效性和安全性。方法:采用紫杉醇175mg/m2,静脉滴注3h,第1天;希罗达1000mg/m2,每天2次,第1~14天,21天为1个周期,连用2个周期后评价疗效。结果:30例中,获得完全缓解(CR)2例,占6.7%;部分缓解(PR)12例,占40.0%;稳定(SD)11例,占36.7%;进展(PD)5例,占16.7%。总有效率(CR+PR)为46.7%。不良反应主要为恶心呕吐、骨髓抑制、腹泻、手足综合征及脱发等。结论:紫杉醇联合卡培他滨二线治疗晚期胃癌疗效较高,安全性好。

    【关键词】晚期胃癌;紫杉醇;卡培他滨;化学治疗

    【中图分类号】R735.2【文献标识码】A【文章编号】1007-8517(2009)10-0036-01

    Study of paclitaxel combined capecitabine for advanced gastric cancer

    WANG Xiaoqing

    (Liaoning TumerHospital,Liaoning ,Shenyang,110042)

    【Abstract】 Objective:We evaluated the antitumour activity and toxicities of paclitaxel and capecitabine as therapy in patients with advanced gastric cancer(AGC).Methods:Patients with histologically confirmed unresectable or metastatic AGC were treated with capecitabine 1000mg/m2 p.o. twice daily on days 1-14 and paclitaxel l75mg/m2i.v. on day 1 every 3 weeks until disease progression or unacceptable toxicities . Results:A total of 2 patients showed complete response and 12 showed partial response making the overall response rate 46.7%.Median time to progression was 6.7 months and median overall survival time was 9.9 months.Grade 3 or 4 adverse events include leukocytopenia ......

您现在查看是摘要页,全文长 5474 字符